一分钟看懂
这是一项关于Diffuse Pleural Mesothelioma的I 期研究，登记的药物或干预包括BMS-986504；Ipilimumab；Nivolumab；5-FU；Leucovorin；Oxaliplatin；Gemcitabine；Platinum，当前状态为招募中。登记地点显示中国Basking Ridge、Middletown、Montvale、Commack等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BMS-986504；Ipilimumab；Nivolumab；5-FU；Leucovorin；Oxaliplatin；Gemcitabine；Platinum · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) · Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) · Uniondale
公开的入选条件
- * Documentation of Disease:
- * Patients must have pathologic confirmation of one of three diseases:
- * Diffuse pleural mesothelioma (DPM)
- * Gastroesophageal carcinoma (GEC) including adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach.
- * PD-L1 CPS ≥1 (using clone 73-10, DAKO)
- * HER2 overexpression negative (using clone 4B5, Ventana): HER2 IHC 0-1+, or HER2 2+ with ISH showing HER2:CEP17 ratio \<2 and average HER2 copy number \<6.0 signals/cell
- * Urothelial carcinoma (UC)
- * Archival tissue is acceptable; diagnosis may be confirmed at any time before or within 28 days of treatment initiation
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07532902；登记信息更新于 2026-09-16。